Verition Fund Management’s Denali Therapeutics DNLI Stock Holding History

Verition Fund Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,629	Closed	-$256K	–	3613
2025 Q3	$256K	Sell	17,629 -33,180	-65%	-$477K	﹤0.01%	3373
2025 Q2	$711K	Buy	50,809 +37,080	+270%	+$522K	﹤0.01%	2712
2025 Q1	$187K	Sell	13,729 -8,872	-39%	-$170K	﹤0.01%	3063
2024 Q4	$461K	Buy	+22,601	New	+$579K	﹤0.01%	2534
2023 Q3	–	Sell	-8,898	Closed	-$263K	–	2420
2023 Q2	$263K	Sell	8,898 -2,884	-24%	-$81.1K	﹤0.01%	1662
2023 Q1	$271K	Buy	+11,782	New	+$324K	﹤0.01%	1582

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Verition Fund Management's DNLI Position: Q4 2025 in Review

Verition Fund Management sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 17,629 shares — an estimated $256K sold.

Verition Fund Management first reported a position in DNLI in Q1 2023 and held it in 6 quarters. The position peaked at $711K in Q2 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Verition Fund Management reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Verition Fund Management sold 17,629 Denali Therapeutics shares in Q4 2025, an estimated $256K.
Verition Fund Management first reported a position in Denali Therapeutics in Q1 2023 and held it in 6 quarters.
Verition Fund Management's Denali Therapeutics position peaked at $711K in Q2 2025.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.